A Phase I/IIa, Open-label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 Month Extended Dosing With AGI - 101H Vaccine in the Treatment of Patients With Advanced Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2016
At a glance
- Drugs AGI 101H (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors AGIRx
- 21 Apr 2016 Status changed from recruiting to discontinued due to problems in funding.
- 16 Jan 2013 Treatment table added.
- 15 Aug 2008 New trial record.